{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:03:36Z","timestamp":1780578216535,"version":"3.54.1"},"reference-count":127,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jtha.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:08:07Z","timestamp":1773756487000},"page":"2007-2024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal gammopathies of thrombotic and hemorrhagic significance: mapping into a classification schema"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-7520","authenticated-orcid":false,"given":"Tajamul H.","family":"Mir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian D.","family":"Santos-Patarroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.03.003_bib1","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtha.2026.03.003_bib3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtha.2026.03.003_bib5","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","article-title":"IgM monoclonal gammopathies of clinical significance: diagnosis and management","volume":"107","author":"Khwaja","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.03.003_bib6","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jtha.2026.03.003_bib8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/annonc\/mdh385","article-title":"The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance","volume":"15","author":"Sallah","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtha.2026.03.003_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0609.2010.01539.x","article-title":"Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism","volume":"86","author":"Gregersen","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib10","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1182\/blood.V126.23.4252.4252","article-title":"No risk of arterial or venous thrombosis in monoclonal gammopathy of undetermined significance: results from a population-based study","volume":"126","author":"Lindqvist","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/bjh.19957","article-title":"Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: results from iStopMM, a prospective population-based screening study","volume":"206","author":"R\u00f6gnvaldsson","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.16774","article-title":"Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance","volume":"192","author":"O\u2019Sullivan","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.thromres.2021.03.015","article-title":"Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"202","author":"Nielsen","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.003_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2003-40965","article-title":"The blood coagulation mechanism in multiple myeloma","volume":"29","author":"Zangari","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/cancers15020480","article-title":"Monoclonal gammopathy of thrombotic significance","volume":"15","author":"Gkalea","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtha.2026.03.003_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2007.1.158","article-title":"Bleeding and thrombosis risks in plasma cell dyscrasias","author":"Eby","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2026.03.003_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic Amyloidosis Recognition, Prognosis, And Therapy: A Systematic Review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.03.003_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ehf2.13701","article-title":"Thromboembolism and bleeding in systemic amyloidosis: a review","volume":"9","author":"Nicol","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jtha.2026.03.003_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3324\/haematol.2015.133900","article-title":"Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis","volume":"101","author":"Bever","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.03.003_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jtha.2026.03.003_bib21","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.03.003_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13506120500537285","article-title":"Natural history of thromboembolism in AL amyloidosis","volume":"13","author":"Halligan","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.jtha.2026.03.003_bib23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.clml.2018.03.005","article-title":"Serum free light chain difference and beta(2) microglobulin levels are risk factors for thromboembolic events in patients with AL amyloidosis","volume":"18","author":"Park","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtha.2026.03.003_bib24","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2001-12-0245","article-title":"Thromboembolic events during treatment with thalidomide","volume":"99","author":"Urbauer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/hrt.74.5.541","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation","volume":"74","author":"Dubrey","year":"1995","journal-title":"Br Heart J"},{"key":"10.1016\/j.jtha.2026.03.003_bib26","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","article-title":"Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation","volume":"106","author":"Rocken","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.03.003_bib27","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.03.003_bib28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jtha.2026.03.003_bib29","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjh.13183","article-title":"New perspectives on the thrombotic complications of haemolysis","volume":"168","author":"L\u2019Acqua","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib31","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2215\/CJN.01600408","article-title":"Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum","volume":"3","author":"Audard","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jtha.2026.03.003_bib32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3816\/CLM.2009.n.021","article-title":"AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity","volume":"9","author":"Palladini","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.jtha.2026.03.003_bib34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2016","author":"Berentsen","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2026.03.003_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.seminhematol.2018.04.002","article-title":"Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease","volume":"55","author":"Berentsen","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib37","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/jcm10081764","article-title":"Thrombotic complications in patients with immune-mediated hemolysis","volume":"10","author":"Capecchi","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib39","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib40","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.thromres.2020.10.010","article-title":"Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management","volume":"198","author":"Sayar","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.003_bib42","first-page":"1290","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"379","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12865-017-0213-0","article-title":"IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report","volume":"18","author":"Wu","year":"2017","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jtha.2026.03.003_bib44","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1055\/a-1366-9379","article-title":"Antiphospholipid syndrome with monoclonal gammopathy\u2014a mechanism for recurrent thrombosis?","volume":"121","author":"Doyle","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.03.003_bib47","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib48","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib49","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.seminhematol.2022.02.005","article-title":"Platelet-activating anti-PF4 disorders: an overview","volume":"59","author":"Warkentin","year":"2022","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib51","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1160\/TH03-10-0649","article-title":"Polymorphonuclear leukocyte and monocyte activation induced by plasma from patients with heparin-induced thrombocytopenia in whole blood","volume":"92","author":"Khairy","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib52","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1160\/TH16-02-0162","article-title":"Role of monocytes and endothelial cells in heparin-induced thrombocytopenia","volume":"116","author":"Madeeva","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib53","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3324\/haematol.2021.280366","article-title":"Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy","volume":"107","author":"Greinacher","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.03.003_bib54","series-title":"Isolation of a monoclonal IgG kappa with functional autoantibody activity against platelet factor 4\/heparin from a patient with a monoclonal gammopathy of undetermined significance and clinically overt heparin thrombocytopenia","author":"Faille","year":"2017"},{"key":"10.1016\/j.jtha.2026.03.003_bib55","doi-asserted-by":"crossref","DOI":"10.11613\/BM.2017.030801","article-title":"False positive immunoassay for heparin-induced thrombocytopenia in the presence of monoclonal gammopathy: a case report","volume":"27","author":"Markovic","year":"2017","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.jtha.2026.03.003_bib56","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMoa2415930","article-title":"VITT-like monoclonal gammopathy of thrombotic significance","volume":"392","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib57","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1056\/NEJMc2506014","article-title":"Monoclonal anti-platelet factor 4 antibodies in recurrent pregnancy loss","volume":"393","author":"Bavli","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100093","article-title":"M protein and the evolving spectrum of platelet-activating anti-PF4 disorders and MGTS and their linkage","volume":"2","author":"Mir","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib59","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMc2406453","article-title":"Myeloma therapy for monoclonal gammopathy of thrombotic significance","volume":"391","author":"Salmasi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/14656566.2024.2328241","article-title":"Therapeutic strategies in FcgammaIIA receptor-dependent thrombosis and thromboinflammation as seen in heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT)","volume":"25","author":"Muller","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jtha.2026.03.003_bib61","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib62","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.kint.2017.04.039","article-title":"Complement-dependent, monoclonal gammapathy-associated thrombotic microangiopathy","volume":"92","author":"Schurder","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtha.2026.03.003_bib63","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtha.2026.03.003_bib64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.ajkd.2021.12.014","article-title":"Complement activation and thrombotic microangiopathy associated with monoclonal gammopathy: a national French case series","volume":"80","author":"Martins","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jtha.2026.03.003_bib65","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/ndt\/gfae191","article-title":"Kidney thrombotic microangiopathy with concurrent monoclonal gammopathy","volume":"40","author":"Tan","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jtha.2026.03.003_bib66","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1002\/ajh.25569","article-title":"Monoclonal gammopathy-associated thrombotic microangiopathy","volume":"94","author":"Yui","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib67","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.3324\/haematol.11475","article-title":"Antibodies against the CUB1-2 domains of ADAMTS13 in a patient with benign monoclonal gammopathy: no causal relationship","volume":"92","author":"Riksen","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.03.003_bib68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/j.ajkd.2024.04.019","article-title":"Clinicopathologic characteristics of crystalglobulin-induced nephropathy: a case series","volume":"84","author":"Nasr","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jtha.2026.03.003_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006643","article-title":"Crystalglobulinemia manifesting as chronic arthralgia and acute limb ischemia: a clinical case report","volume":"96","author":"Abe","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtha.2026.03.003_bib70","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJMra2400092","article-title":"Cryoglobulinemia\u2014one name for two diseases","volume":"391","author":"Cacoub","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib71","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1046\/j.1365-2362.2001.00824.x","article-title":"The cryoglobulins: an overview","volume":"31","author":"Dammacco","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jtha.2026.03.003_bib72","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00005792-200107000-00004","article-title":"Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center","volume":"80","author":"Trejo","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtha.2026.03.003_bib73","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bjh.13196","article-title":"Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases","volume":"168","author":"Harel","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib74","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2016-09-719773","article-title":"How I treat cryoglobulinemia","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib75","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/RHU.0b013e318289e06e","article-title":"Cryofibrinogenemia","volume":"19","author":"Michaud","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jtha.2026.03.003_bib76","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.autrev.2011.04.009","article-title":"A 5-year prospective follow-up study in essential cryofibrinogenemia patients","volume":"10","author":"Belizna","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2026.03.003_bib77","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/kem341","article-title":"Outcome of essential cryofibrinogenaemia in a series of 61 patients","volume":"47","author":"Belizna","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2026.03.003_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ekir.2025.10.022","article-title":"Clinicopathological spectrum and treatment outcomes of cryofibrinogen-associated nephropathies","volume":"11","author":"Dang","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jtha.2026.03.003_bib79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/j.ajkd.2023.07.017","article-title":"Cryoglobulinemic vasculitis in disguise: cryofibrinogenemia as variant of monoclonal gammopathy of renal significance","volume":"83","author":"Gant","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jtha.2026.03.003_bib80","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-2008-1043110","article-title":"[Cryofibrinogenemia caused by monoclonal anti-fibrinogen antibodies]","volume":"121","author":"Zeuner","year":"1996","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.jtha.2026.03.003_bib81","first-page":"1445","article-title":"Cryofibrinogenaemia\u2014a neglected disease","volume":"56","author":"Moiseev","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2026.03.003_bib82","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.amjmed.2009.03.040","article-title":"Cryofibrinogenemia: new insights into clinical and pathogenic features","volume":"122","author":"Saadoun","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib83","first-page":"398","article-title":"Crystal nephropathy: a variant form of myeloma kidney\u2014a case report and review of the literature","volume":"56","author":"Kanno","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jtha.2026.03.003_bib84","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/1097-0142(19930215)71:4<1231::AID-CNCR2820710410>3.0.CO;2-J","article-title":"Crystalglobulinemia syndrome. A manifestation of multiple myeloma","volume":"71","author":"Ball","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.jtha.2026.03.003_bib85","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1532\/IJH97.06074","article-title":"Abnormal N-glycosylation of the immunoglobulin G kappa chain in a multiple myeloma patient with crystalglobulinemia: case report","volume":"85","author":"Hashimoto","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib86","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00296-020-04620-6","article-title":"Crystalglobulinemia manifested as acute renal failure and thrombotic vasculopathy","volume":"40","author":"Gomez-Lechon Quiros","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jtha.2026.03.003_bib87","first-page":"74","article-title":"A case of bilateral renal arterial thrombosis associated with cryocrystalglobulinaemia","volume":"3","author":"Leung","year":"2010","journal-title":"NDT Plus"},{"key":"10.1016\/j.jtha.2026.03.003_bib88","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc1106670","article-title":"The TEMPI syndrome\u2014a novel multisystem disease","volume":"365","author":"Sykes","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib89","article-title":"TEMPI syndrome: update on clinical features, management, and pathogenesis","volume":"13","author":"Xu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jtha.2026.03.003_bib90","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/blood.2019004216","article-title":"The TEMPI syndrome","volume":"135","author":"Sykes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib91","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.thromres.2009.01.004","article-title":"The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease","volume":"125","author":"Cohen","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.003_bib92","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2042098612452291","article-title":"Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance","volume":"3","author":"Palumbo","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jtha.2026.03.003_bib93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2026.03.003_bib94","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.18432","article-title":"Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: analysis of vascular thrombotic events in the GRIFFIN study","volume":"199","author":"Sborov","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib95","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","article-title":"Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias","volume":"145","author":"Eby","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib96","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","article-title":"Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens","volume":"32","author":"van Marion","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtha.2026.03.003_bib97","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/blood-2008-02-140434","article-title":"Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping","volume":"112","author":"Johnson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib98","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ajh.27288","article-title":"Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a comparative systematic review and meta-analysis","volume":"99","author":"Costa","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib99","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib100","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.clml.2023.07.009","article-title":"Venous thromboembolism risk in patients with newly diagnosed multiple myeloma treated with carfilzomib or bortezomib in combination with lenalidomide and dexamethasone","volume":"23","author":"Loncharich","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtha.2026.03.003_bib101","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood.V91.10.3623","article-title":"Clinical significance of inhibitors in acquired von Willebrand syndrome","volume":"91","author":"Mohri","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib102","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.2830090403","article-title":"Pathogenesis of antibody-induced acquired von Willebrand Syndrome","volume":"9","author":"Gan","year":"1980","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib103","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001721-199509000-00010","article-title":"Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor","volume":"6","author":"Mohri","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.03.003_bib104","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/j.1538-7836.2006.02072.x","article-title":"Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor","volume":"4","author":"Coleman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MD.0b013e3182397166","article-title":"Acquired von Willebrand syndrome associated with monoclonal gammopathy: a single-center study of 36 patients","volume":"90","author":"Voisin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtha.2026.03.003_bib106","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/rth2.12481","article-title":"Acquired von Willebrand syndrome in monoclonal gammopathy\u2014a scoping review on hemostatic management","volume":"5","author":"Abou-Ismail","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib107","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood.V92.8.2707","article-title":"Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches","volume":"92","author":"Federici","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib108","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/hae.13639","article-title":"Intravenous immunoglobulin in patients with acquired Von Willebrand syndrome: a single referral centre experience","volume":"25","author":"Bertolino","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.03.003_bib109","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/jth.13317","article-title":"Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy","volume":"14","author":"Lavin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib110","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJM197911083011907","article-title":"Factor X deficiency in primary amyloidosis: resolution after splenectomy","volume":"301","author":"Greipp","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib111","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2016-06-724351","article-title":"Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions","volume":"129","author":"Muczynski","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib112","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajh.2830030303","article-title":"Coagulopathy in amyloidosis: combined deficiency of factors IX and X","volume":"3","author":"McPherson","year":"1977","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib113","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-128-7-199804010-00031","article-title":"AL amyloidosis combined with acquired factor V deficiency","volume":"128","author":"Gatel","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.03.003_bib114","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2025.2476254","article-title":"The global epidemiology of acquired factor X deficiency","volume":"30","author":"Iglay","year":"2025","journal-title":"Hematology"},{"key":"10.1016\/j.jtha.2026.03.003_bib115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.hemonc.2018.05.002","article-title":"Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease","volume":"12","author":"Patel","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtha.2026.03.003_bib116","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ajh.2830110414","article-title":"Factor-X deficiency in amyloidosis: a critical review","volume":"11","author":"Greipp","year":"1981","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib117","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V97.6.1885","article-title":"Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy","volume":"97","author":"Choufani","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.03.003_bib118","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MBC.0000000000000367","article-title":"Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency","volume":"27","author":"Cordes","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.03.003_bib119","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1046\/j.1365-2141.2001.02667.x","article-title":"Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency","volume":"112","author":"Boggio","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib120","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.1983.03330340064034","article-title":"Bleeding manifestations in 100 patients with amyloidosis","volume":"249","author":"Yood","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.03.003_bib121","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.12050","article-title":"Cutaneous haemorrhage induced by minimal trauma as a sign of light chain-associated amyloidosis","volume":"159","author":"Wettle","year":"2012","journal-title":"Br J Haematol"},{"issue":"464\u20135","key":"10.1016\/j.jtha.2026.03.003_bib122","first-page":"467","article-title":"Postproctoscopic periorbital purpura. Primary systemic amyloidosis","volume":"122","author":"Slagel","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtha.2026.03.003_bib123","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.blre.2019.03.004","article-title":"Acquired Glanzmann thrombasthenia: from antibodies to anti-platelet drugs","volume":"36","author":"Nurden","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2026.03.003_bib124","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12959-018-0184-2","article-title":"Combination of acquired von Willebrand syndrome (AVWS) and Glanzmann thrombasthenia in monoclonal gammopathy of uncertain significance (MGUS), a case report","volume":"16","author":"Mayne","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2026.03.003_bib125","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/jth.14424","article-title":"First description of an IgM monoclonal antibody causing alpha(II)(b) beta(3) integrin activation and acquired Glanzmann thrombasthenia associated with macrothrombocytopenia","volume":"17","author":"Pillois","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.003_bib126","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2007.06633.x","article-title":"Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance","volume":"138","author":"Rossi","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.03.003_bib127","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jha2.423","article-title":"Refractory immune thrombocytopenic purpura associated with IgM monoclonal gammopathy of undetermined significance: Successful treatment with tirabrutinib plus conventional therapies","volume":"3","author":"Naka","year":"2022","journal-title":"EJHaem"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626001881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626001881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:06:29Z","timestamp":1780574789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626001881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":127,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1538783626001881"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.03.003","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal gammopathies of thrombotic and hemorrhagic significance: mapping into a classification schema","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}